Mindewei (deuremidevir) / Shanghai Junshi Biosci, Vigonvita Life Sci - LARVOL DELTA

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Completed

Trial completion

The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection. (PubMed, Emerg Microbes Infect) - No abstract available

Journal • Infectious Disease

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Completed | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Jun 2025

Trial completion • Trial completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date

The Mass Balance Study of [14C]JT001 (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd. | Recruiting ➔ Completed

Trial completion

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial primary completion date: Oct 2025 ➔ Jun 2025

Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Mar 2025 ➔ Jul 2025 | Initiation date: Mar 2025 ➔ Jun 2025 | Trial primary completion date: Mar 2025 ➔ Jul 2025

Trial completion date • Trial initiation date • Trial primary completion date

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jan 2025 ➔ Oct 2025 | Trial primary completion date: Jan 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial primary completion date: Sep 2024 ➔ Jan 2025

Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Real-World Study of JT001 for COVID-19 (clinicaltrials.gov) - P=N/A | N=7656 | Active, not recruiting | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd. | Recruiting ➔ Active, not recruiting | N=20000 ➔ 7656 | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Nov 2024

Enrollment change • Enrollment closed • Real-world • Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ May 2024

Trial completion • Trial completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. (PubMed, Lancet Infect Dis) - P3 | "Among patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns."

Journal • P3 data • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

A Real-World Study of JT001 for COVID-19 (clinicaltrials.gov) - P=N/A | N=20000 | Recruiting | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd.

New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study in Elderly Chinese Subjects With Underlying Diseases (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd.

New P1 trial

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd.

New P1 trial • Hepatology • Liver Failure

A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Completed

Trial completion

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Shanghai Vinnerna Biosciences Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Aug 2023 | Trial primary completion date: May 2024 ➔ Aug 2023

Trial completion • Trial completion date • Trial primary completion date • Renal Disease

JT001 (VV116) for the Early Treatment of COVID-19 (clinicaltrials.gov) - P2/3 | N=381 | Terminated | Sponsor: Shanghai JunTop Biosciences Co., LTD | N=1310 ➔ 381 | Trial completion date: Dec 2023 ➔ Mar 2023 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2023 ➔ Mar 2023; Based on the current number of COVID-19 cases and the approval of COVID-19 treatment drugs , the research team is facing great challenges, and it is decided to terminate this study

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19. (PubMed, ACS Pharmacol Transl Sci) - "Simnotrelvir is an oral antiviral agent targeting the 3-chymotrypsin-like protease, which is essential for SARS-CoV-2 viral replication. Previous clinical trials revealed that both deuremidevir and simnotrelvir-ritonavir were effective and well tolerated in the treatment of COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open